Physician profile
Christopher S Ketcherside
NPI 1952523334
$6,277.90
in general payments reported to CMS, 2019-2025
28 companies · $860 in 2025
The $860 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,052 · 2020: $183 · 2021: $888 · 2022: $1,674 · 2023: $728 · 2024: $893 · 2025: $860.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,455 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,454.72 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,602.01 | 2019-2025 | Clareon, Clareon Panoptix Pro, Acrysof Iq Panoptix Uv Iol |
| Rxsight INC | $1,321.03 | 2021-2025 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Dompe US, INC. | $387.99 | 2019-2025 | Oxervate |
| Glaukos Corporation | $344.63 | 2019-2025 | Kxl System (Not Refurbished) |
| Carl Zeiss Meditec USA, INC. | $300.40 | 2021-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $263.61 | 2019-2024 | Tecnis Iol, Tecnis Simplicity |
| Oyster Point Pharma, INC. | $259.06 | 2022-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $257.55 | 2022-2024 | Miebo, Vyzulta, Xiidra |
| Allergan, INC. | $253.99 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $169.50 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $144.54 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $133.40 | 2019-2022 | |
| Coopervision INC. | $112.50 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $105.64 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $88.88 | 2022-2023 | Tepezza |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $83.95 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $82.34 | 2019-2023 | |
| The Cameron-Ehlen Group, INC. | $68.13 | 2020-2023 | Tecnis Iol, Tecnis Simplicity, Healon Pro |
| Amgen INC. | $67.77 | 2024 | Tepezza |
| Carl Zeiss Meditec, INC. | $57.26 | 2021 | |
| Aerie Pharmaceuticals, INC. | $44.77 | 2019 | |
| Thea Pharma INC. | $24.71 | 2023 | Iyuzeh |
| Shire North American Group INC | $20.19 | 2019 | |
| Spark Therapeutics, INC. | $18.42 | 2022 | |
| Genzyme Corporation | $17.91 | 2019 | |
| Eyepoint US, INC. | $16.19 | 2019 | |
| Sight Sciences, INC. | $16.01 | 2022 | |
| Harrow Eye, LLC | $15.52 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Ketcherside listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.